<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976663</url>
  </required_header>
  <id_info>
    <org_study_id>S17L-001</org_study_id>
    <nct_id>NCT01976663</nct_id>
  </id_info>
  <brief_title>A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds</brief_title>
  <official_title>A Prospective, Multicenter, Within-subject Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLIFT® XC Versus Control for the Correction of Moderate to Severe Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, within-subject controlled study of the safety and effectiveness
      of JUVÉDERM VOLIFT® XC versus Control for the correction of moderate to severe nasolabial
      folds (NLFs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2013</start_date>
  <completion_date type="Actual">October 26, 2015</completion_date>
  <primary_completion_date type="Actual">March 17, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Improvement (Reduction) in Nasolabial Fold Severity Using the 5-Point Nasolabial Fold Severity Scale (NLFSS)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Nasolabial fold severity is assessed by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). Mean reduction from baseline in NFLSS is defined as score at baseline minus score at Month 6. The mean reduction indicated improvement (decrease) in nasolabial fold severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Nasolabial Folds With ≥1-Point Improvement</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Nasolabial fold severity is evaluated by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). The percentage of nasolabial folds with ≥1-point improvement from baseline (i.e., decrease in severity) are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nasolabial Folds With ≥1-Point Improvement</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Nasolabial fold severity is evaluated by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). The percentage of nasolabial folds with ≥1-point improvement from baseline (i.e., decrease in severity) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Improvement in Overall Nasolabial Folds FACE-Q Score</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Subjects evaluate nasolabial folds on the 5-item Nasolabial Folds module of the FACE-Q questionnaire. Responses to the 5 items are combined to create a scale score that ranged from 0 to 100, where 0 indicates that the subject is extremely bothered and 100 indicates that the subject is not all bothered by the appearance of the nasolabial fold. Improvement is defined as the score at Month 12 minus the baseline score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Moderate to Severe Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>VOLIFT® XC NLFs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control NLFs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasolabial folds treated with Control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVEDERM VOLIFT® XC</intervention_name>
    <description>Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.</description>
    <arm_group_label>VOLIFT® XC NLFs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.</description>
    <arm_group_label>Control NLFs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 visible moderate to severe nasolabial folds

          -  Agree to refrain from undergoing other anti-wrinkle/volumizing treatments in the lower
             two-thirds of the face for the duration of the study

        Exclusion Criteria:

          -  Undergone facial tissue augmentation with dermal fillers in the lower two-thirds of
             the face within the past 12 months

          -  Undergone facial tissue augmentation with fat injections, botulinum toxin injections
             in the lower two-thirds of the face, mesotherapy, or cosmetic facial procedures in the
             face or neck within the past 6 months

          -  Received semi-permanent fillers or permanent facial implants anywhere in the lower
             face
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitiligo and Pigmentation Institute of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute, LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2013</study_first_posted>
  <results_first_submitted>April 14, 2017</results_first_submitted>
  <results_first_submitted_qc>April 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2017</results_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 126 subjects were enrolled in the study (Enrolled Population); 123 subjects were randomized and treated (Modified Intent-to-Treat).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>JUVEDERM VOLIFT® XC</title>
          <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC on one side and Control on the other side.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Completed 18 mos but no repeat treatment</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent-to-Treat (mITT): all randomized and treated subjects</population>
      <group_list>
        <group group_id="B1">
          <title>JUVEDERM VOLIFT® XC</title>
          <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC on one side and Control on the other side.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>30 to 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Improvement (Reduction) in Nasolabial Fold Severity Using the 5-Point Nasolabial Fold Severity Scale (NLFSS)</title>
        <description>Nasolabial fold severity is assessed by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). Mean reduction from baseline in NFLSS is defined as score at baseline minus score at Month 6. The mean reduction indicated improvement (decrease) in nasolabial fold severity.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>modified intent-to-treat (mITT): all randomized and treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM VOLIFT® XC</title>
            <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nasolabial folds treated with Control.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Improvement (Reduction) in Nasolabial Fold Severity Using the 5-Point Nasolabial Fold Severity Scale (NLFSS)</title>
          <description>Nasolabial fold severity is assessed by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). Mean reduction from baseline in NFLSS is defined as score at baseline minus score at Month 6. The mean reduction indicated improvement (decrease) in nasolabial fold severity.</description>
          <population>modified intent-to-treat (mITT): all randomized and treated subjects</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.49"/>
                    <measurement group_id="O2" value="2.6" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=117, 117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.67"/>
                    <measurement group_id="O2" value="1.3" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Nasolabial Folds With ≥1-Point Improvement</title>
        <description>Nasolabial fold severity is evaluated by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). The percentage of nasolabial folds with ≥1-point improvement from baseline (i.e., decrease in severity) are reported.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>modified intent-to-treat (mITT): all randomized and treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM VOLIFT® XC</title>
            <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nasolabial folds treated with Control.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nasolabial Folds With ≥1-Point Improvement</title>
          <description>Nasolabial fold severity is evaluated by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). The percentage of nasolabial folds with ≥1-point improvement from baseline (i.e., decrease in severity) are reported.</description>
          <population>modified intent-to-treat (mITT): all randomized and treated subjects</population>
          <units>Percentage of Nasolabial Folds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" spread="0.49" lower_limit="87.0" upper_limit="97.0"/>
                    <measurement group_id="O2" value="86.3" lower_limit="78.7" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nasolabial Folds With ≥1-Point Improvement</title>
        <description>Nasolabial fold severity is evaluated by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). The percentage of nasolabial folds with ≥1-point improvement from baseline (i.e., decrease in severity) are reported.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>modified intent-to-treat (mITT): all randomized and treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM VOLIFT® XC</title>
            <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nasolabial folds treated with Control.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nasolabial Folds With ≥1-Point Improvement</title>
          <description>Nasolabial fold severity is evaluated by the Evaluating Investigator on the 5-point Nasolabial Fold Severity Scale (ranging from 0=None [no wrinkle] to 4=Extreme [very deep wrinkle, redundant fold]). The percentage of nasolabial folds with ≥1-point improvement from baseline (i.e., decrease in severity) are reported.</description>
          <population>modified intent-to-treat (mITT): all randomized and treated subjects</population>
          <units>Percentage of Nasolabial Folds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" spread="0.49" lower_limit="47.9" upper_limit="66.8"/>
                    <measurement group_id="O2" value="56.6" lower_limit="47.0" upper_limit="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Improvement in Overall Nasolabial Folds FACE-Q Score</title>
        <description>Subjects evaluate nasolabial folds on the 5-item Nasolabial Folds module of the FACE-Q questionnaire. Responses to the 5 items are combined to create a scale score that ranged from 0 to 100, where 0 indicates that the subject is extremely bothered and 100 indicates that the subject is not all bothered by the appearance of the nasolabial fold. Improvement is defined as the score at Month 12 minus the baseline score.</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>modified intent-to-treat (mITT): all randomized and treated subjects with data at this time point</population>
        <group_list>
          <group group_id="O1">
            <title>JUVEDERM VOLIFT® XC</title>
            <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Nasolabial folds treated with Control.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Improvement in Overall Nasolabial Folds FACE-Q Score</title>
          <description>Subjects evaluate nasolabial folds on the 5-item Nasolabial Folds module of the FACE-Q questionnaire. Responses to the 5 items are combined to create a scale score that ranged from 0 to 100, where 0 indicates that the subject is extremely bothered and 100 indicates that the subject is not all bothered by the appearance of the nasolabial fold. Improvement is defined as the score at Month 12 minus the baseline score.</description>
          <population>modified intent-to-treat (mITT): all randomized and treated subjects with data at this time point</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="14.70"/>
                    <measurement group_id="O2" value="32.0" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=112, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="23.08"/>
                    <measurement group_id="O2" value="23.4" spread="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population includes all subjects who received at least 1 treatment. The Safety Population is used to assess adverse events and serious adverse events. Adverse events and serious adverse events are presented by treatment side for events occurring at the nasolabial folds, or combined for events that did not occur at the nasolabial folds.</desc>
      <group_list>
        <group group_id="E1">
          <title>JUVEDERM VOLIFT® XC During Initial/Touch Up</title>
          <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC during the Initial/Touch Up period.</description>
        </group>
        <group group_id="E2">
          <title>Control During Initial/Touch Up Treatment Period</title>
          <description>Nasolabial folds treated with Control during the Initial/Touch Up period.</description>
        </group>
        <group group_id="E3">
          <title>Not at NLF During Initial/Touch Up Treatment Period</title>
          <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC on one side and Control on the other side.</description>
        </group>
        <group group_id="E4">
          <title>JUVEDERM VOLIFT® XC Asymmetry Correction/Repeat Treatment</title>
          <description>Nasolabial folds treated with JUVEDERM VOLIFT® XC during the Asymmetry Correction/Repeat Treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>Subject 10003-3015; occurred 1 year after treatment; assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>Assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Subject 10003-3015; occurred 1 year after treatment; assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <description>Assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <description>Assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Hypoxia</sub_title>
                <description>Subject 10003-3015; occurred 1 year after treatment; assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <description>Subject 10003-3015; occurred 1 year after treatment; assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Subject 10003-3015; occurred 1 year after treatment; assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <description>Assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>Subject 10003-3015; occurred 1 year after treatment; assessed as unrelated to treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection Site Mass</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allergan Inc.,</name_or_title>
      <organization>Allergan, Inc</organization>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

